A synthesized peptide derived from human ARHGEF3, corresponding to a region within C-terminal amino acids.
Conjugate
Unconjugated
Applications
Application Notes
WB 1:500-1:1000 IF/ICC 1:100-1:500
General Notes
This product (Catalog No. DPABH-26661) is a rabbit-derived polyclonal antibody raised against human ARHGEF3. This antibody exhibits cross-reactivity with ARHGEF3 from mouse and rat. It has been affinity purified by Protein A. Rho-like GTPases are involved in a variety of cellular processes, and they are activated by binding GTP and inactivated by conversion of GTP to GDP by their intrinsic GTPase activity. Guanine nucleotide exchange factors (GEFs) accelerate the GTPase activity of Rho GTPases by catalyzing their release of bound GDP. This gene encodes a guanine nucleotide exchange factor, which specifically activates two members of the Rho GTPase family: RHOA and RHOB, both of which have a role in bone cell biology. It has been identified that genetic variation in this gene plays a role in the determination of bone mineral density (BMD), indicating the implication of this gene in postmenopausal osteoporosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. DPABH-26661 is suitable for use in WB 1 (500-1:1000), IF/ICC 1 (100-1:500) applications. DPABH-26661 is supplied as a liquid formulation in Phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
My Review for Rabbit Anti-Human ARHGEF3 (C-terminal) Polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.